Sensorion (FR0012596468 – ALSEN), a leading clinical-stage biotechnology company focused on innovative therapies for hearing loss, has announced its participation in the 36th World Congress of Audiology (WCA) in Paris from September 19-22, 2024.
The company will host a symposium on September 20, 2024, at 12:30 pm CET, titled:
“Are We on the Verge of a Hearing Loss Revolution?”
The symposium will be chaired by Professor Natalie Loundon, an ENT Surgeon at the Pediatric Hospital Necker-Enfants Malades in Paris. The event will feature three sessions:
- Hearing Preservation: Advances in Cisplatin-Induced Ototoxicity and Cochlear Implantation
This session will cover recent developments in hearing preservation related to cisplatin-induced ototoxicity and cochlear implantation, presented by Professor Yann Nguyen (Hôpital de la Pitié Salpêtrière, Paris) and Professor Stephen O’Leary (University of Melbourne, Australia). - Gene Therapy: New Hope for Congenital Hearing Disorders
Professor Catherine Birman (Sydney Cochlear Implant Centre, Australia) will discuss gene therapy approaches for congenital profound deafness. - Future Perspectives: The Impact of Emerging Therapies
Professor Natalie Loundon will lead this session, exploring the future implications of new therapies on patient management, followed by a Q&A segment.
About Sensorion
Sensorion is at the forefront of developing novel therapies to address hearing loss, an area with significant unmet medical needs. The company utilizes a unique R&D platform to deepen its understanding of inner ear diseases and identify effective drug targets.
Sensorion’s gene therapy programs include SENS-501 (OTOF-GT), currently in a Phase 1/2 trial, targeting deafness from otoferlin gene mutations, and GJB2-GT, aimed at hearing loss from GJB2 gene mutations. Additionally, the company is developing biomarkers to enhance the diagnosis of these conditions.
Sensorion’s portfolio also features clinical-stage small molecule treatments, including SENS-401 (Arazasetron), which is progressing through a Phase 2 study for cisplatin-induced ototoxicity and cochlear implantation, as well as having completed a Phase 2 study for sudden sensorineural hearing loss (SSNHL) in January 2022.
